Major Review: High-THC Cannabis Products Tied to Psychosis and Addiction, Mixed Results for Anxiety and Depression
Across 99 studies and 221,000 participants, high-concentration THC products showed consistently unfavorable associations with psychosis and cannabis use disorder, while evidence for anxiety and depression was mixed depending on whether use was therapeutic or recreational.
Quick Facts
What This Study Found
In non-therapeutic studies, high-concentration THC showed unfavorable associations with psychosis/schizophrenia (70% of studies) and cannabis use disorder (75%). For anxiety, 53% of non-therapeutic studies found unfavorable associations, while 47% of therapeutic studies found benefits. For depression, 41% non-therapeutic studies were unfavorable while 48% of therapeutic studies showed benefits. No therapeutic studies reported favorable results for psychosis.
Key Numbers
99 studies; 221,097 participants; 70% showed unfavorable psychosis associations; 75% showed unfavorable CUD associations; 47% therapeutic benefit for anxiety; 48% therapeutic benefit for depression; >95% of studies had moderate or high risk of bias
How They Did This
Systematic review searching MEDLINE through May 2025 plus five additional databases through August 2024. High-concentration THC defined as >5mg or >10% THC per serving, or labeled as concentrate/shatter/dab. 99 studies (221,097 participants) including 42% RCTs, 47% observational, 11% other interventional. Published in Annals of Internal Medicine.
Why This Research Matters
As legalized cannabis markets increasingly feature high-potency products, this landmark review provides the clearest picture yet of mental health risks. The distinction between therapeutic and recreational use reveals an important nuance: context matters for whether high-THC products help or harm.
The Bigger Picture
This is one of the most comprehensive reviews to date on high-potency cannabis and mental health. Its publication in Annals of Internal Medicine signals mainstream medicine taking the potency question seriously. The therapeutic vs. non-therapeutic distinction could reshape how we think about cannabis regulation.
What This Study Doesn't Tell Us
Over 95% of included studies had moderate or high risk of bias. Limited evaluation of contemporary products (concentrates, vapes). Definition of "high concentration" varied across studies. Cannot establish causation from observational studies.
Questions This Raises
- ?Should cannabis regulations include THC concentration caps?
- ?At what potency threshold do mental health risks increase sharply?
- ?Why do therapeutic and non-therapeutic contexts produce different anxiety and depression outcomes?
Trust & Context
- Key Stat:
- 99 studies, 221,097 participants reviewed
- Evidence Grade:
- Large-scale systematic review published in a top-tier medical journal, though over 95% of included studies had moderate or high risk of bias.
- Study Age:
- Published in 2025 with searches through May 2025.
- Original Title:
- High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review.
- Published In:
- Annals of internal medicine, 178(10), 1429-1440 (2025)
- Authors:
- Rittiphairoj, Thanitsara, Leslie, Louis, Oberste, Jean-Pierre, Yim, Tsz Wing, Tung, Gregory, Bero, Lisa, Riggs, Paula, Hutchison, Kent, Samet, Jonathan, Li, Tianjing
- Database ID:
- RTHC-07495
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Are high-THC products more dangerous than lower-potency cannabis?
This review found consistently unfavorable associations between high-THC products and psychosis (70% of studies) and cannabis use disorder (75%). The evidence is strongest for these two outcomes.
Can high-THC cannabis help with anxiety or depression?
The results were mixed. In therapeutic contexts (using cannabis to treat a condition), about half of studies found benefits for anxiety and depression. In non-therapeutic use, unfavorable associations were more common.
What counts as high-concentration THC?
The review defined it as more than 5mg or more than 10% THC per serving, or products labeled as concentrates, shatter, or dab. Many products in legal markets exceed these thresholds.
Read More on RethinkTHC
- THC-purity-potency-label-meaning
- dab-concentrate-addiction-withdrawal
- delta-8-addiction-withdrawal
- edible-addiction-withdrawal-different
- edibles-psychosis-emergency-room
- healthiest-way-to-consume-cannabis
- how-cannabis-products-made-concentrates-edibles
- laced-weed-fentanyl-contaminated-vape
- legal-weed-vs-street-weed-quality-safety
- quitting-dabs-withdrawal
- quitting-edibles-withdrawal
- sativa-vs-indica-difference-myth
- weed-potency-withdrawal
Cite This Study
https://rethinkthc.com/research/RTHC-07495APA
Rittiphairoj, Thanitsara; Leslie, Louis; Oberste, Jean-Pierre; Yim, Tsz Wing; Tung, Gregory; Bero, Lisa; Riggs, Paula; Hutchison, Kent; Samet, Jonathan; Li, Tianjing. (2025). High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review.. Annals of internal medicine, 178(10), 1429-1440. https://doi.org/10.7326/ANNALS-24-03819
MLA
Rittiphairoj, Thanitsara, et al. "High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review.." Annals of internal medicine, 2025. https://doi.org/10.7326/ANNALS-24-03819
RethinkTHC
RethinkTHC Research Database. "High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Pro..." RTHC-07495. Retrieved from https://rethinkthc.com/research/rittiphairoj-2025-highconcentration-delta9tetrahydrocannabinol-cannabis-products
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.